Tibet Duo Rui Pharmaceutical Hits Day Low Amid Price Pressure at CNY 74.10

Tibet Duo Rui Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 6.21% and reaching an intraday low of CNY 74.10. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 1.09% on the same day. Over the past week, Tibet Duo Rui has seen a decrease of 6.6%, while its monthly performance remains positive at 17.86%. However, the company has faced challenges in the long term, with net sales declining at an annual rate of 15.87% and operating profit showing a drastic decrease of 376.81% over the last five years. Despite a remarkable one-year performance of 238.33%, the company has reported negative results for the last 13 consecutive quarters, raising concerns about its financial stability. The stock's high debt-to-equity ratio and low return on equity of -28.67% further highlight the risks associated with investing in Tibet Duo Rui. As the company navigates these financial hurdles, its market position remains under scrutiny.